Optimizing Iron Deficiency Management in CKD: IV Iron Replacement Therapy Amid the Latest KDIGO Guidelines
NephrologyOptimizing Iron Deficiency Management in CKD: IV Iron Replacement Therapy Amid the Latest KDIGO Guidelines
Brendon Neuen, MBBS, PhD
Hidden Hunger in CKD: A Case-Based Perspective
Clinician's RoundtableHidden Hunger in CKD: A Case-Based Perspective
Jeanette Andrade, PhD, RDN, LDN, FAND
The Silent Clues Behind IgA Nephropathy Diagnosis
Clinician's RoundtableThe Silent Clues Behind IgA Nephropathy Diagnosis
Abdallah Geara, MD
Rethinking Potassium Restriction in Chronic Kidney Disease Management
Clinician's RoundtableRethinking Potassium Restriction in Chronic Kidney Disease Management
Deborah Clegg, PhD
Dietary Potassium in CKD: Navigating Risks, Sources, and Patient Factors
Clinician's RoundtableDietary Potassium in CKD: Navigating Risks, Sources, and Patient Factors
Deborah Clegg, PhD
Early Detection as a Turning Point in IgA Nephropathy Care
Clinician's RoundtableEarly Detection as a Turning Point in IgA Nephropathy Care
Abdallah Geara, MD
- advertisement
Navigating KDIGO Practice Guideline Recommendations to Maximize Proteinuria Reduction in Patients With IgAN
CME/CENavigating KDIGO Practice Guideline Recommendations to Maximize Proteinuria Reduction in Patients With IgAN
Chee Kay Cheung, MBChB, PhD, FRCP
Claudia Seikrit, MD
Vous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
CME/CEVous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD
Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
CME/CETransforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
Richard Lafayette, MD, FACP
Ankana Daga, MD
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
CME/CEStuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD
Patient Voices and Provider Partnerships to Advance Cardio-Kidney-Metabolic Outcomes
CME/CEPatient Voices and Provider Partnerships to Advance Cardio-Kidney-Metabolic Outcomes
Jay B. Wish, MD
Richard Lafayette, MD, FACP
Dana Rizk, MD
Hong Zhang
Suzuki Yusuke, MD, PhD
- advertisement
Rethinking Cardiovascular Risk: Uncovering the Blind Spots
Conversations in CV Risk AssessmentRethinking Cardiovascular Risk: Uncovering the Blind Spots
Jennifer Caudle, DO, FACOFP
Javed Butler, MD, MPH, MBA
Elevating CV Risk Assessment: Why uACR Deserves a Seat at the Table
Conversations in CV Risk AssessmentElevating CV Risk Assessment: Why uACR Deserves a Seat at the Table
Brian P. McDonough, MD, FAAFP
Javier Morales, MD, FACP, FACE
Primary Care and Cardiology: Shared Responsibility in Albuminuria Detection
Conversations in CV Risk AssessmentPrimary Care and Cardiology: Shared Responsibility in Albuminuria Detection
Jennifer Caudle, DO, FACOFP
Javed Butler, MD, MPH, MBA
Martha Gulati, MD, MS, FACC
Challenging Cases in IgA Nephropathy and Identifying Patients for Specialized Care
Medical Industry FeatureChallenging Cases in IgA Nephropathy and Identifying Patients for Specialized Care
Jaimini Patel, PharmD, BCCCP
Sayna Norouzi, MD
The Role of APRIL and the 4-Hit Process in the Pathogenesis of IgA Nephropathy
Medical Industry FeatureThe Role of APRIL and the 4-Hit Process in the Pathogenesis of IgA Nephropathy
Edgar V. Lerma, MD, FACP, FASN, FPSN (Hon)
Luis E. Vélez, MD
Navigating IgA Nephropathy: Pathogenesis, The Role Of APRIL & The 4-Hit Process, & A Patient Case Study
Medical Industry FeatureNavigating IgA Nephropathy: Pathogenesis, The Role Of APRIL & The 4-Hit Process, & A Patient Case Study
Abigail Yancey, PharmD, BCPS
Kartik Kalra, MD
- 05/01/2026
- 05/01/2026
- 05/01/2026
- 04/30/2026
- 04/28/2026
- 04/27/2026